ArticleEBioMedicine2016
Enho Mutations Causing Low Adropin: A Possible Pathomechanism of MPO-ANCA Associated Lung Injury.
Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- Adropin modulates pancreatic cell proliferation and glutathione levels in an animal model of type 1 diabetes mellitus.Animal models and experimental medicine · 2025Article
- A Potential Role of Adropin in Inflammatory Rheumatic Diseases-What Do We Know So Far?Biomedicines · 2025Review
- Adropin: a key player in immune cell homeostasis and regulation of inflammation in several diseases.Frontiers in immunology · 2025Review
- Unveiling the multifaceted role of adropin in various diseases (Review).International journal of molecular medicine · 2024Review
- The role of serum adropin in determining the clinical outcomes of patients with traumatic brain injury: a case-control study.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Development and validation of a new diagnostic prediction model of ENHO and NOX4 for early diagnosis of systemic sclerosis.Frontiers in immunology · 2024Article
- Low-dose adropin stimulates inflammasome activation of macrophage via mitochondrial ROS involved in colorectal cancer progression.BMC cancer · 2023Article
- Adropin attenuates pancreatitis‑associated lung injury through PPARγ phosphorylation‑related macrophage polarization.International journal of molecular medicine · 2023Article
- Selective deficiency of UCP-1 and adropin may lead to different subtypes of anti-neutrophil cytoplasmic antibody-associated vasculitis.Genes and immunity · 2023Article
- Interorgan communication with the liver: novel mechanisms and therapeutic targets.Frontiers in immunology · 2023Review
- Adropin's Role in Energy Homeostasis and Metabolic Disorders.International journal of molecular sciences · 2022Review
- Serum Adropin Levels in Patients with Rheumatoid Arthritis.Life (Basel, Switzerland) · 2022Article
- Inflammatory response and matrix metalloproteinases in chronic kidney failure: Modulation by adropin and spexin.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Organ-organ communication: The liver's perspective.Theranostics · 2021Review
- A Review of Adropin as the Medium of Dialogue between Energy Regulation and Immune Regulation.Oxidative medicine and cellular longevity · 2020Review
- Pulmonary vasculitis.Journal of thoracic disease · 2018Review
- SP100B Expression Indexed Hemorrhage in Mouse Models of Cerebral Hemorrhage.Indian journal of clinical biochemistry : IJCB · 2018Article
- A Novel S100A8/A9 Induced Fingerprint of Mesenchymal Stem Cells associated with Enhanced Wound Healing.Scientific reports · 2018Article
- Analysis of Antineutrophil Cytoplasm Antibody from 118 730 Patients in Tertiary Hospitals in Jiangxi Province, China.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Adropin deficiency worsens HFD-induced metabolic defects.Cell death & disease · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyeloperoxidase (MPO) anti-neutrophil cytoplasm autoantibody (ANCA)-associated vasculitis commonly causes life-threatening pulmonary alveolar hemorrhage or fibrosis. Only a limited number of candidate gene variants have been explored, but hitherto, are not widely confirmed. In the present study, we investigated the importance of energy homeostasis associated gene (Enho) mutations and adropin deficiency in the development of MPO-ANCA associated lung injury.
methodsWe analyzed the peripheral blood mononuclear cells from 152 unrelated patients and 220 population-matched healthy individuals for genetic variations in Enho. Functional studies with adropin knockout (AdrKO) on C57BL/6J mice were also performed.
findingsSequencing revealed six patients with p.Ser43Thr and that five patients shared Cys56Trp amino acid substitution in Enho. Serum concentration of adropin was significantly lower in patients than that of the healthy subjects (P<0.0001), especially those with Enho mutations. In vivo, homo- and heterozygous carriers of the null adropin allele exhibited MPO-ANCA associated pulmonary alveolar hemorrhage as compared to wild-type mice. AdrKO mice exhibit reduced eNOS (Ser1177) and Akt1 (Ser473) phosphorylation and loss of Treg cells.
interpretationOur findings indicate that the presence of Enho mutations or adropin-deficiency is a probable molecular basis for the initial events triggered in MPO-ANCA associated lung injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.